Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
INTRODUCTION:Reports of therapeutic failure to meglumine antimoniate (MA) and miltefosine in cutaneous leishmaniasis (CL) varies between species, populations and geographic regions. This study aimed to determine the clinical, drug-related factors, and Leishmania species associated with treatment fai...
Saved in:
Main Authors: | Maria Del Mar Castro (Author), Alexandra Cossio (Author), Carlos Velasco (Author), Lyda Osorio (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
by: Brandon A Berger, et al.
Published: (2017) -
Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019) -
Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
by: Olga Lucía Fernández, et al.
Published: (2024) -
Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
by: Mohamad Javad Yazdanpanah, et al.
Published: (2011) -
Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019)